QP not present in Company: Prohibition of Supply
Recommendation
11/12 February 2025
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
A new Non-Compliance Report (NCR, Report No: 2017090955) was published on the EudraGMDP site. On 21 September 2017, the Danish Medicines Agency performed an inspection at EuroPharma.DK ApS in Denmark. EuroPharma.DK ApS performs parallel import, repacking and distribution of pharmaceutical products.
During that inspection, it was considered that the secondary packing operations at the site do not comply with Good Manufacturing Practice. This was also based on the following observations:
- QP not present in company for supervision and competent interaction with staff and management
- QA department understaffed
- Inadequate follow-up and implementation of CAPAs
- Insufficient handling of deviations and complaints
- Inadequate GDP implementation
As a consequence, the respective manufacturing authorisation was suspended and medicinal products must not be re-packed by EuroPharma DK or any of their contract manufacturers and must not be released and distributed. What's interesting is the fact that the GMP certificate which was withdrawn was just issued after an inspection on 8 March 2017.
Source: EudraGMDP Database (Report # 2017090955)
Related GMP News
18.12.2024What are the GMP Requirements for Consultants?
18.12.2024ICH published updated Q8/Q9/Q10 Questions & Answers Document
11.12.2024European Shortages Monitoring Platform (ESMP) has gone live
27.11.2024Windsor Framework Explainer Document published
27.11.2024EMA Comments on the Role of the QP in Supply Chain Traceability